castrate resistant prostate cancer CRPC epidemiology insights failed
DelveInsight’s ‘Castrate-Resistant Prostate Cancer (CRPC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted CRPC epidemiology in the 7MM, i.e., the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
CRPC Understanding
Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm.
According to the Cancer Treatment Centres of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells. The exact cause of prostate cancer is unknown. However, several things can increase the risk of developing this condition like age, family history, diet, high testosterone level, genome changes, and race.
In the majority of the cases, the symptoms of prostate cancer are not apparent in the early stages of the disease. The symptoms of prostate cancer may be different for each man, and other conditions may cause some of these symptoms like blood in semen, erectile dysfunction, painful ejaculation, pain in pelvic area, and numbness in legs.
Patients undergo regular prostate cancer screening before symptoms appear. Screening may involve one or more of the following tests: prostate-specific antigen (PSA), digital rectal exam (DRE), prostate ultrasound, prostate MRI, prostate Mp-MRI.
CRPC is defined by disease progression despite androgen depletion therapy (ADT). It may present as a continuous rise in serum prostate-specific antigen (PSA) levels, the advancement of pre-existing disease, or the appearance of new metastases.
Epidemiology Perspective by DelveInsight
The CRPC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The CRPC epidemiology data are studied through CRPC possible division to give a better understanding of the Disease scenario in the 7MM.
The disease epidemiology covered in the report provides historical as well as forecasted CRPC epidemiology [segmented as Total Prevalent Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer, Age-specific Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer by Clinical Stages, Total Non-metastatic and Metastatic Cases of CRPC, and Total Treated Cases of Non-metastatic and Metastatic CRPC] scenario of CRPC in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
CRPC Detailed Epidemiology Segmentation
• The total cases of CRPC in the 7MM were found to be 265,891 in 2017 which is expected to grow during the study period, i.e., 2017–2030.
• In total cases of CRPC, nmCRPC cases accounted for 71% of the cases i.e., 188,573 cases in 2017. On the other hand, mCRPC accounted for 77,318 cases in 2017.
• Estimates show that the highest cases of CRPC are in the United States, followed by Germany, France, Japan, and Italy in 2017.
• In 2017, there were 127,805 cases of CRPC in the United States, while in Germany these cases were 38,365 which accounted for second-highest cases in the total cases of CRPC in the 7MM.
• Japan accounted for 26,724 cases of CRPC in 2017, which is approximately 10% of the total 7MM diagnosed prevalent cases of CRPC.
Scope of the Report
• The CRPC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The CRPC Report and Model provide an overview of the risk factors and global trends of CRPC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of CRPC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of CRPC.
• The report provides the segmentation of the prostate cancer epidemiology by diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the prostate cancer epidemiology by age-specific cases in the 7MM.
• The report provides the segmentation of the prostate cancer epidemiology by clinical stages in the 7MM.
• The report provides the segmentation of the prostate cancer epidemiology by non-metastatic and metastatic Cases of CRPC in the 7MM.
• The report provides the segmentation of the prostate cancer epidemiology by treated non-metastatic and metastatic Cases of CRPC in the 7MM.
Report Highlights
• 11-Year Forecast of CRPC epidemiology
• 7MM Coverage
• Total Prevalent Cases of Prostate Cancer
• Diagnosed prevalent cases segmentation: Age-Specific, by Clinical-Stage, Cases of mCRPC and nmCRPC
• Treated cases of mCRPC and nmCRPC
KOL-Views
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over CRPC scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CRPC?
• What are the key findings pertaining to the CRPC epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of CRPC across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of CRPC?
Reasons to buy
The CRPC Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global CRPC market
• Quantify patient populations in the global CRPC market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CRPC therapeutics in each of the markets covered
• Understand the magnitude of CRPC population by its severity
• The CRPC epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The CRPC Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
